Absence of 6-hydroxydopamine in the rat brain after treatment with stimulants and other dopaminergic agents: a mass fragmentographic study

J Neurochem. 1993 Oct;61(4):1369-75. doi: 10.1111/j.1471-4159.1993.tb13630.x.

Abstract

Formation of 6-hydroxydopamine (6-OHDA) from dopamine has been hypothesized to mediate neurodegeneration induced by some psychostimulants. Although the emergence of a 6-OHDA-like substance was reported in the striatum of methamphetamine-treated rats, this substance has not been identified by a direct approach. We used mass fragmentography to search for 6-OHDA in the rat frontal cortex and striatum after the administration of a number of drugs including 3,4-dihydroxyphenyl-L-alanine, methamphetamine, amphetamine, and cocaine, all of which increase synaptic dopamine. No 6-OHDA was detected after the acute systemic administration of these agents. Intraventricular administration of 6-OHDA (10 micrograms/rat) produced measurable concentrations of 6-OHDA that were higher in the striatum than in the frontal cortex. Intraventricular administration of 2,4,5-trihydroxyphenyl-D,L-alanine (6-OHDOPA; 10 micrograms/rat) produced similar concentrations of 6-OHDA in both regions. Pargyline, but not carbidopa (alpha-methyl-dopa-hydrazine), enhanced the effect of intraperitoneal 6-OHDOPA administration (80 mg/kg). We conclude that (1) 6-OHDOPA can cross the blood-brain barrier and is converted to 6-OHDA in the brain, (2) 6-OHDA is a substrate for monoamine oxidase(s) and therefore a search for its purported deaminated metabolite is warranted, and (3) acute treatment with the above stimulants either does not lead to the formation of 6-OHDA or produces concentrations below the detection limit of the assay (< 34 pg/mg of protein).

MeSH terms

  • Animals
  • Brain / metabolism*
  • Carbidopa / pharmacology
  • Corpus Striatum / metabolism
  • Dihydroxyphenylalanine / analogs & derivatives
  • Dihydroxyphenylalanine / chemistry
  • Dihydroxyphenylalanine / pharmacology
  • Dopamine Agents / pharmacology*
  • Drug Combinations
  • Drug Stability
  • Frontal Lobe / metabolism
  • Gas Chromatography-Mass Spectrometry
  • Injections, Intraventricular
  • Male
  • Oxidopamine / chemistry
  • Oxidopamine / metabolism*
  • Oxidopamine / pharmacology
  • Pargyline / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Stimulation, Chemical

Substances

  • Dopamine Agents
  • Drug Combinations
  • 6-hydroxydopa
  • Dihydroxyphenylalanine
  • Oxidopamine
  • Pargyline
  • Carbidopa